Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell…
Pharmaceuticals, Biotechnology and Life Sciences
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell…
BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing…
WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an…
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics…
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D. The facility will…
Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a…
– Moderated discussion with leading expert in Fibrostenotic Crohn’s Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan –…
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of…
Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in Q3 2026…
Current Clinical Trial Focus is MSS Colorectal Cancer, Ovarian Clear-Cell Carcinoma, and Soft-Tissue SarcomaDENVER, Aug. 25, 2025 (GLOBE NEWSWIRE) —…